Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC)
Wenguang Wang, Zhilu Gan, Qiang Liu, Shenshen Yan, Rexiti Mulati, Yujie Wang
Abstract
. In addition, the ccRCC cells were exposed to DDP treatment, and we surprisingly found that upregulation of CXCR4 increased DDP-resistance in ccRCC cells, and conversely, CXCR4 ablation sensitized ccRCC cells to DDP stimulation. Taken together, we concluded that CXCR4 ablation hindered cancer progression and enhanced DDP-sensitivity in ccRCC, and the present study identified a novel therapeutic biomarker for ccRCC.
Topics & Concepts
Cancer researchClear cell renal cell carcinomaCXC chemokine receptorsCXCR4Chemokine receptorOncogeneCell growthGene silencingCancerBiologyCisplatinTumor progressionEpithelial–mesenchymal transitionChemokineMedicineCell cyclePathologyMetastasisImmunologyRenal cell carcinomaChemotherapyInflammationBiochemistryGeneticsGeneCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosisImmunotherapy and Immune Responses